About Sequence Bio
Sequence Bio is a company based in St. John's (Canada) founded in 2013. Sequence Bio has raised $5.47 million across 4 funding rounds from investors including Y Combinator, DCVC and Killick Capital. Sequence Bio offers products and services including Genetics Platform and Discovery Cohorts. Sequence Bio operates in a competitive market with competitors including Omniome, Novogene Corporation, HitGen, Singular Genomics and Slingshot Bioscience, among others.
- Headquarter St. John's, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sequence Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.47 M (USD)
in 4 rounds
-
Latest Funding Round
$1.32 M (USD), Seed
Jul 30, 2019
-
Investors
Y Combinator
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sequence Bio
Sequence Bio offers a comprehensive portfolio of products and services, including Genetics Platform and Discovery Cohorts.
Platform for systems biology to identify disease signals in genetics.
Service providing powered cohorts for disease research and drug development.
People of Sequence Bio
Unlock access to complete
Funding Insights of Sequence Bio
Sequence Bio has successfully raised a total of $5.47M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $1.32 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sequence Bio
Sequence Bio has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Y Combinator, DCVC and Killick Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Killick Capital is engaged in private equity investments in Canada.
|
Locked | Locked | Locked |
Investor details for Sequence Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sequence Bio
Investment portfolio details for Sequence Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sequence Bio
Detailed financials for Sequence Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sequence Bio Comparisons
Peer comparison for Sequence Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sequence Bio
Sequence Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Omniome, Novogene Corporation, HitGen, Singular Genomics and Slingshot Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
DNA-encoded libraries are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Next-generation gene sequencing and multi-omics technologies are provided.
|
|
| Locked | Locked | Locked |
Next-generation synthetic cells are developed for diagnostics and therapeutics.
|
|
| Locked | Locked | Locked |
Next-generation sequencing and genomics services are provided globally.
|
Detailed competitors of Sequence Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sequence Bio
Complete news archive for Sequence Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sequence Bio
Sequence Bio was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Sequence Bio is headquartered in St. John's, Canada. It is registered at St. John's, Newfoundland And Labrador, Canada.
Chris C Gardner is the current CEO of Sequence Bio.
Sequence Bio is a funded company, having raised a total of $5.47M across 4 funding rounds to date.
Sequence Bio was established in 2013 in Newfoundland and Labrador, Canada, as a data-driven biotechnology company. A 100,000-person genome sequencing project is led by the firm to analyze genetic data for medical applications. Operations center on genomic research and data processing to support advancements in disease treatment and pharmaceutical development within the biotechnology sector. The company is headquartered in the region with Chris C. Gardner serving as CEO and President.
Sequence Bio's top competitors include Novogene Corporation, BGI and Singular Genomics.
Sequence Bio offers Genetics Platform and Discovery Cohorts.
Sequence Bio has 5 investors. Key investors include Y Combinator, DCVC, Killick Capital, Klister Credit, and Pelorus Venture Capital.